Compare · RXST vs STAA
RXST vs STAA
Side-by-side comparison of RxSight Inc. (RXST) and STAAR Surgical Company (STAA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RXST and STAA operate in Ophthalmic Goods (Health Care), so they compete in similar markets.
- STAA is the larger of the two at $1.41B, about 7.1x RXST ($198.3M).
- STAA has been more active in the news (10 items in the past 4 weeks vs 2 for RXST).
- Both have 25 recent analyst ratings on file.
- Company
- RxSight Inc.
- STAAR Surgical Company
- Price
- $4.77-3.25%
- $28.22-0.98%
- Market cap
- $198.3M
- $1.41B
- 1M return
- -
- +3.37%
- 1Y return
- -
- +69.03%
- Industry
- Ophthalmic Goods
- Ophthalmic Goods
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 2
- 10
- Recent ratings
- 25
- 25
RxSight Inc.
RxSight, Inc., a medical technology company, develops light adjustable lens (LAL) to improve uncorrected visual acuity that can be adjusted enhance uncorrected visual acuity after cataract surgery. It also offers RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is based in Aliso Viejo, California.
STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone intraocular lenses, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. STAAR Surgical Company markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, and Italy. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Latest RXST
- SEC Form SD filed by RxSight Inc.
- RxSight, Inc. to Present at the Stifel 2026 Virtual Ophthalmology Forum
- SEC Form 10-Q filed by RxSight Inc.
- RxSight, Inc. Reports First Quarter 2026 Results and Reiterates Full-Year Sales Outlook
- RxSight Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- RxSight, Inc. to Present at the Bank of America Healthcare Conference
- SEC Form DEFA14A filed by RxSight Inc.
- SEC Form DEF 14A filed by RxSight Inc.
- RxSight, Inc. to Report First Quarter 2026 Financial Results on May 6
- SEC Form 4 filed by Goldshleger Ilya
Latest STAA
- STAAR Surgical Announces Participation in Upcoming Investor Conferences
- Chief Development Officer Michna Magda was granted 19,795 shares and covered exercise/tax liability with 9,703 shares, increasing direct ownership by 31% to 42,783 units (SEC Form 4)
- Interim Co-CEO and CFO Andrews Deborah J was granted 15,699 shares and covered exercise/tax liability with 5,632 shares (SEC Form 4)
- Interim Co-CEO and Pres. & COO Foust Warren covered exercise/tax liability with 16,785 shares and was granted 32,990 shares, increasing direct ownership by 24% to 83,112 units (SEC Form 4)
- STAAR Surgical upgraded by Wedbush with a new price target
- SEC Form 10-Q filed by STAAR Surgical Company
- STAAR Surgical Company filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- STAAR Surgical Reports First Quarter 2026 Results; Issues Shareholder Letter
- Interim Co-CEO and Pres. & COO Foust Warren covered exercise/tax liability with 3,448 shares, decreasing direct ownership by 5% to 66,917 units (SEC Form 4)
- Chief Development Officer Michna Magda covered exercise/tax liability with 1,680 shares, decreasing direct ownership by 5% to 32,691 units (SEC Form 4)